Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabestomig (AZD7789) in relapsed/refractory classical Hodgkin lymphoma
NCT05216835Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Primary completion
- Aug 2024
- Modality
- Bispecific Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of sabestomig in classical Hodgkin lymphoma (cHL) (3 cohorts), sponsored by AstraZeneca. Primary endpoints: Adverse Events, Dose-limiting Toxicities at 28 days and 2 more. Started Mar 2022; status: completed.
02
Drugs
sabestomig
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05216835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216835.